News
-
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
Telomir Pharmaceuticals reports preclinical findings showing Telomir-1 reduces PSA levels in prostate cancer cells, indicating potential treatment response. CEO and scientific perspectives highlighted -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
New data from Telomir Pharmaceuticals show Telomir-1 effectively modulates iron levels in human keratinocytes, key for its epigenetic mechanism. Telomir-1 provides strong intracellular iron reduction surpassing Deferoxamine -
